Today: 24 January 2026
Subscribe

Khadija Saeed

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

AppLovin (APP) Stock Jumps Above $620 as AI Adtech Boom Meets Regulatory Risk – Latest News, Forecasts and Analysis (December 2, 2025)

AppLovin (APP) Stock Jumps Above $620 as AI Adtech Boom Meets Regulatory Risk – Latest News, Forecasts and Analysis (December 2, 2025)

AppLovin Corporation (NASDAQ: APP) is back in the spotlight. On December 2, 2025, the AI‑driven advertising platform’s stock pushed higher again, trading around $623.59, up roughly 4% on the day and extending an already explosive run in 2025. Smartkarma At the same time, the company is juggling regulatory probes, insider selling, and a stretched valuation, even as Wall Street price…
2 December 2025
···
Intel Stock (INTC) on December 2, 2025: Apple Foundry Buzz, Malaysia Expansion and Q3 Rebound Fuel a High‑Stakes Rally

Intel Stock (INTC) on December 2, 2025: Apple Foundry Buzz, Malaysia Expansion and Q3 Rebound Fuel a High‑Stakes Rally

Intel Corporation (NASDAQ: INTC) is back in the spotlight. As of December 2, 2025, Intel stock is trading around $40 per share, near its 52‑week highs and roughly double its level at the start of 2025. MarketBeat Behind that move is a potent mix of Apple foundry rumors, fresh government and partner capital, a return to profitability, and renewed AI…
2 December 2025
····
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025. Eli Lilly Stock Today: High Price, High Expectations As of mid‑day on December 2, 2025, Eli Lilly and Company (NYSE: LLY) is trading…
2 December 2025
····
Coinbase (COIN) Stock on December 2, 2025: Price Drop, Transparency Report Shock, and 2026 Forecasts

Coinbase (COIN) Stock on December 2, 2025: Price Drop, Transparency Report Shock, and 2026 Forecasts

Updated: December 2, 2025 Coinbase stock today: sharp pullback after a crypto shakeout Coinbase Global, Inc. (NASDAQ: COIN) is trading around $260 per share in early afternoon trading on December 2, 2025, after a volatile start to the month. The move follows an almost 5% slide on Monday, December 1, when Coinbase shares closed near $260, dragged down by a…
2 December 2025
····
Robinhood (HOOD) Stock Today, December 2, 2025: Price, Forecast, Prediction Markets Pivot and Crypto Risks

Robinhood (HOOD) Stock Today, December 2, 2025: Price, Forecast, Prediction Markets Pivot and Crypto Risks

Robinhood Markets, Inc. (NASDAQ: HOOD) is back in the spotlight on December 2, 2025, after a year in which the stock has more than tripled and become one of the S&P 500’s standout performers. Barchart At the same time, the shares sit more than 20% below their October peak, analysts remain bullish on the long term, and fresh worries about…
2 December 2025
····
Micron Technology (MU) Stock on December 2, 2025: AI Memory Supercycle, $300–$338 Targets and the $9.6B Japan Bet

Micron Technology (MU) Stock on December 2, 2025: AI Memory Supercycle, $300–$338 Targets and the $9.6B Japan Bet

(SEO):Micron Technology (NASDAQ: MU) stock is riding an AI-fueled memory supercycle, with Wall Street targets up to $338, a new $9.6B HBM fab in Japan, and key earnings on December 17, 2025. Here’s what investors need to know today. Key Takeaways Micron Stock Today: Price, Performance and Valuation As of early trading on December 2, 2025, Micron Technology, Inc. (NASDAQ:…
2 December 2025
····
Palantir Stock Today: AI Superstar or Bubble Risk? Latest PLTR News, Forecasts and Analysis (Dec. 2, 2025)

Palantir Stock Today: AI Superstar or Bubble Risk? Latest PLTR News, Forecasts and Analysis (Dec. 2, 2025)

Key Takeaways Where Palantir Stock Stands on December 2, 2025 As of mid‑day trading on Dec. 2, 2025, Palantir Technologies (NASDAQ: PLTR) changes hands at about $167.49 per share, giving the company a market capitalization near $400 billion. Companies Market Cap Key snapshot: In other words: Palantir is trading like a hyper‑growth AI franchise, not a typical software stock. Even…
2 December 2025
····
AMD Stock on December 2, 2025: AI Supercycle, New Mega-Deals and Fresh Forecasts for NASDAQ: AMD

AMD Stock on December 2, 2025: AI Supercycle, New Mega-Deals and Fresh Forecasts for NASDAQ: AMD

Advanced Micro Devices (AMD, NASDAQ: AMD) remains at the center of the AI-chip boom on December 2, 2025. The stock is stabilizing after a bruising November sell-off, while new AI infrastructure deals, M&A headlines and updated Wall Street forecasts are reshaping the narrative around one of 2025’s most-watched names. This article is for informational purposes only and is not financial…
2 December 2025
····
Strategy Inc (MSTR) Stock Plunges as Bitcoin Slides and $1.44 Billion Cash Reserve Splits Opinion – Latest News, Forecasts and Analysis (2 December 2025)

Strategy Inc (MSTR) Stock Plunges as Bitcoin Slides and $1.44 Billion Cash Reserve Splits Opinion – Latest News, Forecasts and Analysis (2 December 2025)

Strategy Inc — the Bitcoin-heavy company formerly known as MicroStrategy — is back in the spotlight after another brutal two days for both its stock and for Bitcoin itself. As of mid-day on December 2, 2025, Strategy’s Nasdaq-listed shares (ticker: MSTR) trade around $171, down sharply from their autumn highs and roughly 50–60% below peak levels, with three‑month returns near…
2 December 2025
····
Meta Platforms (META) Stock Today – December 2, 2025: AI Spending Shock, New Price Targets and 2025–26 Forecast

Meta Platforms (META) Stock Today – December 2, 2025: AI Spending Shock, New Price Targets and 2025–26 Forecast

Meta Platforms, Inc. (NASDAQ: META) is starting December trading in the mid‑$600s, still digesting a sharp post‑earnings sell‑off but backed by a fresh wave of bullish Wall Street forecasts and heavy institutional buying. As of early trading on December 2, 2025, Meta stock is hovering around $640–$645 per share, almost flat versus Monday’s close of $640.87, giving the company a…
2 December 2025
····
Alphabet (GOOG) Stock on December 2, 2025: AI Breakthroughs, Buffett’s Bet and Wall Street’s 2026 Forecast

Alphabet (GOOG) Stock on December 2, 2025: AI Breakthroughs, Buffett’s Bet and Wall Street’s 2026 Forecast

Alphabet Inc.’s Class C shares (NASDAQ: GOOG) enter December trading near record highs, riding a powerful AI-driven rally and fresh upgrades from Wall Street. As of the December 1 close, GOOG traded at $315.12, giving Alphabet a market capitalization of about $3.8 trillion and leaving the stock just below its 52‑week high around $329. StockAnalysis Yet despite a roughly 70%…
2 December 2025
····
Amazon (AMZN) Stock on December 2, 2025: AI Mega‑Deals, Fee Cuts and 30‑Minute Delivery Fuel a Fresh Bull Case

Amazon (AMZN) Stock on December 2, 2025: AI Mega‑Deals, Fee Cuts and 30‑Minute Delivery Fuel a Fresh Bull Case

Amazon.com, Inc. (NASDAQ: AMZN) is quietly back in the spotlight. On December 2, 2025, Amazon stock trades around $233.88, up about 0.3% on the day, with a market capitalization near $2.5 trillion. That leaves shares roughly 10% below their 52‑week high of $258.60, despite a powerful run in profits and a growing AI narrative around AWS. StockAnalysis At the same…
2 December 2025
····
1 … 743 744 745 746 747 … 805

Stock Market Today

  • Zealand Pharma (CPSE:ZEAL) Shares Underperform Amid Valuation Debate
    January 24, 2026, 4:07 PM EST. Zealand Pharma's shares have fallen 45% over the past year, despite positive 3- and 5-year returns. The stock trades at DKK426 versus a fair value estimate near DKK746, highlighting a substantial valuation gap. The company's alliance with Roche to commercialize petrelintide aims to capitalize on the growing obesity and metabolic disorders market, potentially driving long-term growth. However, the promising outlook depends heavily on clinical trial success and partnership milestones. Investors face a complex risk-reward scenario, with aggressive revenue and earnings expectations built into current valuations. Analysts suggest carefully reviewing the narrative assumptions and key risks before adjusting positions or exploring other healthcare stocks.
Go toTop